Cellular Mechanisms of a New Pyrazinone Compound that Induces Apoptosis in SKOV-3 Cells |
Wang, Guan
(Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, Jilin University)
Jiang, Meng-Ying (Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, Jilin University) Meng, Ying (Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University) Song, Hong-Rui (Key Laboratory of Structure-Based Drug Design and Discovery, Ministry of Education, Shenyang Pharmaceutical University) Shi, Wei (Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, Jilin University) |
1 | Rouzier R, Bergzoll C, Brun JL, et al (2010). The role of lymph node resection in ovarian cancer: analysis of the Surveillance, Epidemiology, and End Results (SEER) database. BJOG, 117, 1451-8. DOI ScienceOn |
2 | Sachdeva MS (1998). Drug targeting systems for cancer chemothe- erapy. Expert Opin Investig Drugs, 7, 1849-4. DOI ScienceOn |
3 | Siegel R, Ward E, Brawley O, Jemal A (2011). Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on prematurecacer deaths. CACancer J Clin, 61, 212-6. DOI |
4 | Wagner U, du Bois A, Pfisterer J, et al (2007). Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinumtaxane based therapya phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6). Gynecol Oncol, 105, 132-7. DOI ScienceOn |
5 | Wahl H, Tan L, Griffith K, Choi M, Liu JR (2007). Curcumin enhances nces Apo2L/TRAIL-induced apoptosis in chemoresistant ovarian cancer cells. Gynecol Oncol, 105, 104-2. DOI ScienceOn |
6 | Zamboni WC, Strychor S, Joseph E (2008). Tumor, tissue, and pl-asma pharma cokinetic studies and antitumor response studies of docetaxel in combination with 9-nitrocamptothecin in mice bear-ing SKOV-3 human ovarian xenografts. Cancer Chemother Pharmacol, 62, 417-6. DOI |
7 | Zhang Y, Ge Y, Chen Y, et al (2012). Cellular and molecular mechanisms of silibinin induces cell-cycle arrest and apoptosis on HeLa cells. Cell Biochem Funct, 30, 243-8. DOI ScienceOn |
8 | Metzger-Filho O, Moulin C, D'Hondt V (2010). First-line systemic treatment of ovarian cancer: a critical re'view of available eviden- ce and expectations for future directions. Curr Opin Oncol, 22, 513-0. DOI ScienceOn |
9 | du Bois A, Quinn M, Thigpen T, et al (2005). 2004 consensus stat- ements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian C-ancer Consensus Conference (GCIG OCCC 2004). Ann Oncol, 16, viii7-2. |
10 | McGuire WP, Hoskins WJ, Brady MF, et al (1996). Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patpatients with stage III and stage IV ovarian cancer. N Engl J Med, 334, 1-6. DOI ScienceOn |
11 | Rogalska A, Gajek A, Szwed M, Jozwiak Z, Marczak A (2011). T- he role of reactive oxygen species in WP 631-induced death of human ovarian cancer cells: a comparison with the effect of do- xorubicin. Toxicol In Vitro, 25, 1712-0. DOI ScienceOn |
12 | Meng Y, Wang G, Li Y, et al (2013). Synthesis and biolo-gical evaluation of new pyrrolopyrazinone compounds as potential antitumor agents. Chin Chem Lett, 24, 619-1. DOI ScienceOn |
13 | Petrucci E, Pasquini L, Petronelli A, et al (2007). A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol Oncol, 105, 481-2. DOI ScienceOn |
14 | Piotrowska H, Myszkowski K Ziolkowska A, et al (2012). Resver- atrol analogue 3,4,4',5-tetramethoxystilbene inhibits growth, arr-ests cell cycle and induces apoptosis in ovarian SKOV-3 and A-2780 cancer cells. Toxicol Appl Pharmacol, 263, 53-0. DOI ScienceOn |
15 | Rogalska A, Marczak A, Gajek A, et al (2013). Induction of apopt-osis in human ovarian cancer cells by new anticancer compoun-ds, epothilone A and B. Toxicol In Vitro, 27, 239-9. DOI ScienceOn |
16 | Abuharbeid S, Apel J, Zugmaier G, et al (2005). Inhibition of HER-2 by three independent targeting strategies increases paclitaxel resistance of SKOV-3 ovarian carcinoma cells. Naunyn Schmiedebergs Arch Pharmacol, 371, 141-1. DOI ScienceOn |
17 | Chauhan SC, Kumar D, Jaggi M (2009). Mucins in ovarian cancer diagnosis and therapy. J Ovarian Res, 12, 21-9. |
18 | Degterev A, Boyce M, Yuan J (2003). A decade of caspases. Onco- gene, 22, 8543-7. DOI ScienceOn |
19 | Descoteaux C, Brasseur K, Leblanc V, et al (2012). Design of novel tyrosinenitrogen mustard hybrid molecules active against uterine, ovarian and brea- st cancer cell lines. Steroids, 77, 403-2. DOI ScienceOn |
20 | Dejean LM, Martinez-Caballero S, Kinnally KW (2006). Is MAC the knife that cuts cytochrome c from mitochondria during apop-tosis? Cell Death Differ, 13, 1387-5. DOI ScienceOn |